568 related articles for article (PubMed ID: 20413326)
21. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
22. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
23. Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Schlom J; Palena C; Greiner JW; Tsang KY; Grosenbach DW; Sabzevari H; Gulley JL; Arlen PM; Kass E; Hodge JW
Dev Biol (Basel); 2004; 116():27-47. PubMed ID: 15603182
[No Abstract] [Full Text] [Related]
24. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
26. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
27. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
28. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
Van den Eynde B
Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
[TBL] [Abstract][Full Text] [Related]
29. Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines.
Schirrmacher V
Cancer Surv; 1992; 13():129-54. PubMed ID: 1423321
[TBL] [Abstract][Full Text] [Related]
30. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
31. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
32. Cancer vaccines: preclinical studies and novel strategies.
Palena C; Abrams SI; Schlom J; Hodge JW
Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.
Mattner F; Fleitmann JK; Lingnau K; Schmidt W; Egyed A; Fritz J; Zauner W; Wittmann B; Gorny I; Berger M; Kirlappos H; Otava A; Birnstiel ML; Buschle M
Cancer Res; 2002 Mar; 62(5):1477-80. PubMed ID: 11888923
[TBL] [Abstract][Full Text] [Related]
34. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
35. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
36. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
37. Peptide-based immunotherapy for multiple myeloma: current approaches.
Zhou FL; Meng S; Zhang WG; Wei YC; Cao XM; Bai GG; Wang BY
Vaccine; 2010 Aug; 28(37):5939-46. PubMed ID: 20619381
[TBL] [Abstract][Full Text] [Related]
38. Adjuvants for cancer vaccines.
Dubensky TW; Reed SG
Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
[TBL] [Abstract][Full Text] [Related]
39. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
Coulie PG
Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.
Hevey R; Ling CC
Future Med Chem; 2012 Mar; 4(4):545-84. PubMed ID: 22416779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
